Validation of an Alzheimer's Disease Assessment Battery in Asian Participants With Mild to Moderate Alzheimer's Disease

Joan HQ Shen¹, Qi Shen², Holly Yu³, Jin-Shei Lai⁴, Jennifer L Beaumont⁵, Zhenxin Zhang⁶, Huali Wang⁷, Seong Yoon Kim⁸, Christopher Chen⁹, Timothy Kwok¹⁰, Shuu-Jiun Wang¹¹, Dong Young Lee¹², John Harrison¹³ and Jeffrey Cummings^14*

¹Pfizer Inc, Shanghai, China

²Clinical Science, Pfizer Inc, Collegeville, PA, USA

³Pfizer Inc.500 Arcola Rd, Collegeville, PA, USA

⁴Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA

⁵Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA

⁶Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Services, Beijing, China

⁷Dementia Care & Research Center, Clinical Research Division, Peking University Institute of Mental Health, Beijing, China

⁸Department of Psychiatry, Asian Medical Center, University of Ulsan, Medical College, Seoul, Korea

⁹Department of Pharmacology, National University of Singapore, Singapore

¹⁰Department of Medicine & Therapeutics (Geriatric division), Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

¹¹Faculty of Medicine, National Yang-Ming University School of Medicine, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan

¹²Department of Neuropsychiatry, Seoul National University College of Medicine, Seoul, Korea

¹³Principal Consultant, Metis Cognition Ltd. Kilmington Common, UK, Honorary Senior Lecturer, Department of Medicine, Imperial College, London, UK

¹⁴Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV; Cleveland, OH: Weston, FL, USA